Literature DB >> 27502068

Anti-Müllerian hormone for prediction of ovarian response in Chinese infertile women undergoing IVF/ICSI cycles: a prospective, multi-centre, observational study.

Rong Li1, Fei Gong2, Yimin Zhu3, Wenhui Fang4, Jing Yang5, Jiayin Liu6, Linli Hu7, Dongzi Yang8, Xiaoyan Liang9, Jie Qiao10.   

Abstract

This study explored the correlation between serum anti-Müllerian hormone (AMH) concentration and the number of retrieved oocytes after ovarian stimulation in Chinese infertile women undergoing assisted reproductive technology treatment and AMH cut-off values predicting low and high ovarian response. This was a prospective, multi-centre, observational study. A total of 615 subjects were included in nine assisted reproductive centres in China for outcome analysis. Subjects received assisted reproductive technology treatment and used recombinant human FSH (r-HFSH) or r-HFSH plus recombinant LH (rLH) for ovarian stimulation according to conventional treatment regimens. The main outcome variables were correlations between AMH and the number of retrieved oocytes and the cut-off values of AMH predicting low and high ovarian response. Serum AMH concentration was positively correlated with the number of oocytes retrieved in Chinese infertile women treated with IVF/intracytoplasmic sperm injection (ICSI) (Pearson correlation coefficient = 0.4754, P < 0.0001). The optimal AMH cut-off value was 2.6 ng/ml (sensitivity: 81.28%, specificity: 59.51%) in predicting high and normal response, and 1.1 ng/ml (sensitivity: 52.27%, specificity: 87.23%) in predicting low and normal response. In conclusion, serum AMH concentration can be used as a biomarker to predict ovarian response in Chinese infertile women treated with assisted reproductive technology.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  AMH cut-off values; assisted reproductive technology; number of oocytes; ovarian response

Mesh:

Substances:

Year:  2016        PMID: 27502068     DOI: 10.1016/j.rbmo.2016.07.003

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  6 in total

1.  An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review.

Authors:  B S Eisele; G C Villalba Silva; C Bessow; R Donato; V K Genro; J S Cunha-Filho
Journal:  J Assist Reprod Genet       Date:  2021-03-31       Impact factor: 3.357

2.  Reliability of AMH and AFC measurements and their correlation: a large multicenter study.

Authors:  Philippe Arvis; Catherine Rongières; Olivier Pirrello; Philippe Lehert
Journal:  J Assist Reprod Genet       Date:  2022-03-03       Impact factor: 3.357

3.  Prediction of Fertilization Disorders in the In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Retrospective Study of 106,728 Treatment Cycles.

Authors:  Tian Tian; Lixue Chen; Rui Yang; Xiaoyu Long; Qin Li; Yongxiu Hao; Fei Kong; Rong Li; Yuanyuan Wang; Jie Qiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-20       Impact factor: 6.055

4.  Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF.

Authors:  Jialyu Huang; Jiaying Lin; Hongyuan Gao; Yun Wang; Xiuxian Zhu; Xuefeng Lu; Bian Wang; Xinyan Fan; Renfei Cai; Yanping Kuang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-28       Impact factor: 5.555

5.  Machine Learning-Based Modeling of Ovarian Response and the Quantitative Evaluation of Comprehensive Impact Features.

Authors:  Liu Liu; Fujin Shen; Hua Liang; Zhe Yang; Jing Yang; Jiao Chen
Journal:  Diagnostics (Basel)       Date:  2022-02-14

6.  Evaluation of Ovarian Reserve Tests and Age in the Prediction of Poor Ovarian Response to Controlled Ovarian Stimulation-A Real-World Data Analysis of 89,002 Patients.

Authors:  Xue Wang; Lei Jin; Yun-Dong Mao; Juan-Zi Shi; Rui Huang; Yue-Ning Jiang; Cui-Lian Zhang; Xiao-Yan Liang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-30       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.